Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CollPlant Biotechnologies (CLGN) EPS (Basic) (2017 - 2025)

CollPlant Biotechnologies filings provide 9 years of EPS (Basic) readings, the most recent being $1.63 for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 379.41% to $1.63 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.31, a 230.0% increase, with the full-year FY2025 number at $0.94, down 35.17% from a year prior.
  • EPS (Basic) hit $1.63 in Q4 2025 for CollPlant Biotechnologies, up from $0.27 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $1.63 in Q4 2025 to a low of -$2.67 in Q4 2022.
  • Median EPS (Basic) over the past 5 years was $0.31 (2023), compared with a mean of $0.09.
  • Biggest five-year swings in EPS (Basic): surged 400.0% in 2021 and later crashed 584.62% in 2022.
  • CollPlant Biotechnologies' EPS (Basic) stood at -$0.39 in 2021, then crashed by 584.62% to -$2.67 in 2022, then soared by 84.27% to -$0.42 in 2023, then surged by 180.95% to $0.34 in 2024, then soared by 379.41% to $1.63 in 2025.
  • The last three reported values for EPS (Basic) were $1.63 (Q4 2025), $0.27 (Q3 2025), and $0.28 (Q2 2025) per Business Quant data.